dc.identifier.uri |
http://dx.doi.org/10.15488/608 |
|
dc.identifier.uri |
http://www.repo.uni-hannover.de/handle/123456789/632 |
|
dc.contributor.author |
Schuchardt, Jan Philipp
|
|
dc.contributor.author |
Schneider, Inga
|
|
dc.contributor.author |
Meyer, Henrike
|
|
dc.contributor.author |
Neubronner, Juliane
|
|
dc.contributor.author |
Schacky, C. von
|
|
dc.contributor.author |
Hahn, Andreas
|
|
dc.date.accessioned |
2016-11-02T08:33:43Z |
|
dc.date.available |
2016-11-02T08:33:43Z |
|
dc.date.issued |
2011 |
|
dc.identifier.citation |
Schuchardt, Jan Philipp; Schneider, Inga; Meyer, Henrike; Neubronner, Juliane; Von Schacky, C. et al.: Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - A comparative bioavailability study of fish oil vs. krill oil. In: Lipids in Health and Disease 10 (2011), 145. DOI: http://dx.doi.org/10.1186/1476-511X-10-145 |
|
dc.description.abstract |
Background: Bioavailability of omega-3 fatty acids (FA) depends on their chemical form. Superior bioavailability has been suggested for phospholipid (PL) bound omega-3 FA in krill oil, but identical doses of different chemical forms have not been compared. Methods. In a double-blinded crossover trial, we compared the uptake of three EPA+DHA formulations derived from fish oil (re-esterified triacylglycerides [rTAG], ethyl-esters [EE]) and krill oil (mainly PL). Changes of the FA compositions in plasma PL were used as a proxy for bioavailability. Twelve healthy young men (mean age 31 y) were randomized to 1680 mg EPA+DHA given either as rTAG, EE or krill oil. FA levels in plasma PL were analyzed pre-dose and 2, 4, 6, 8, 24, 48, and 72 h after capsule ingestion. Additionally, the proportion of free EPA and DHA in the applied supplements was analyzed. Results: The highest incorporation of EPA+DHA into plasma PL was provoked by krill oil (mean AUC 0-72 h: 80.03 34.71%*h), followed by fish oil rTAG (mean AUC 0-72 h: 59.78 36.75%*h) and EE (mean AUC 0-72 h: 47.53 38.42%*h). Due to high standard deviation values, there were no significant differences for DHA and the sum of EPA+DHA levels between the three treatments. However, a trend (p = 0.057) was observed for the differences in EPA bioavailability. Statistical pair-wise group comparison's revealed a trend (p = 0.086) between rTAG and krill oil. FA analysis of the supplements showed that the krill oil sample contained 22% of the total EPA amount as free EPA and 21% of the total DHA amount as free DHA, while the two fish oil samples did not contain any free FA. Conclusion: Further studies with a larger sample size carried out over a longer period are needed to substantiate our findings and to determine differences in EPA+DHA bioavailability between three common chemical forms of LC n-3 FA (rTAG, EE and krill oil). The unexpected high content of free EPA and DHA in krill oil, which might have a significant influence on the availability of EPA+DHA from krill oil, should be investigated in more depth and taken into consideration in future trials. |
eng |
dc.language.iso |
eng |
|
dc.publisher |
London : BioMed Central Ltd. |
|
dc.relation.ispartofseries |
Lipids in Health and Disease 10 (2011) |
|
dc.rights |
CC BY 2.0 Unported |
|
dc.rights.uri |
https://creativecommons.org/licenses/by/2.0/ |
|
dc.subject |
absorption |
eng |
dc.subject |
bioavailability |
eng |
dc.subject |
ethyl esters |
eng |
dc.subject |
fish oil |
eng |
dc.subject |
krill oil |
eng |
dc.subject |
re-esterified triacylglycerides |
eng |
dc.subject |
uptake |
eng |
dc.subject |
docosahexaenoic acid |
eng |
dc.subject |
edible oil |
eng |
dc.subject |
fish oil |
eng |
dc.subject |
icosapentaenoic acid |
eng |
dc.subject |
krill oil |
eng |
dc.subject |
nko |
eng |
dc.subject |
omega 3 fatty acid |
eng |
dc.subject |
phospholipid |
eng |
dc.subject |
unclassified drug |
eng |
dc.subject |
docosahexaenoic acid |
eng |
dc.subject |
fish oil |
eng |
dc.subject |
icosapentaenoic acid |
eng |
dc.subject |
phospholipid |
eng |
dc.subject |
adult |
eng |
dc.subject |
area under the curve |
eng |
dc.subject |
article |
eng |
dc.subject |
body weight |
eng |
dc.subject |
controlled study |
eng |
dc.subject |
crossover procedure |
eng |
dc.subject |
diet supplementation |
eng |
dc.subject |
double blind procedure |
eng |
dc.subject |
drug bioavailability |
eng |
dc.subject |
drug blood level |
eng |
dc.subject |
drug formulation |
eng |
dc.subject |
human |
eng |
dc.subject |
human experiment |
eng |
dc.subject |
intermethod comparison |
eng |
dc.subject |
male |
eng |
dc.subject |
maximum plasma concentration |
eng |
dc.subject |
normal human |
eng |
dc.subject |
phospholipid blood level |
eng |
dc.subject |
randomized controlled trial |
eng |
dc.subject |
time to maximum plasma concentration |
eng |
dc.subject |
animal |
eng |
dc.subject |
blood |
eng |
dc.subject |
chemistry |
eng |
dc.subject |
clinical trial |
eng |
dc.subject |
comparative study |
eng |
dc.subject |
controlled clinical trial |
eng |
dc.subject |
Euphausiacea |
eng |
dc.subject |
Euphausiacea |
eng |
dc.subject |
Adult |
eng |
dc.subject |
Animals |
eng |
dc.subject |
Area Under Curve |
eng |
dc.subject |
Chemistry, Pharmaceutical |
eng |
dc.subject |
Docosahexaenoic Acids |
eng |
dc.subject |
Double-Blind Method |
eng |
dc.subject |
Eicosapentaenoic Acid |
eng |
dc.subject |
Euphausiacea |
eng |
dc.subject |
Fish Oils |
eng |
dc.subject |
Humans |
eng |
dc.subject |
Male |
eng |
dc.subject |
Phospholipids |
eng |
dc.subject.ddc |
500 | Naturwissenschaften
|
ger |
dc.subject.ddc |
570 | Biowissenschaften, Biologie
|
ger |
dc.title |
Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations - A comparative bioavailability study of fish oil vs. krill oil |
|
dc.type |
Article |
|
dc.type |
Text |
|
dc.relation.issn |
1476-511X |
|
dc.relation.doi |
http://dx.doi.org/10.1186/1476-511X-10-145 |
|
dc.bibliographicCitation.volume |
10 |
|
dc.bibliographicCitation.firstPage |
145 |
|
dc.description.version |
publishedVersion |
|
tib.accessRights |
frei zug�nglich |
|